Abpro Bio Co., Ltd. (KOSDAQ:195990)
South Korea · Delayed Price · Currency is KRW 972.00
-7.00 (-0.72%)
At close: Jun 5, 2026
Abpro Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 30,937 | 31,923 | 31,663 | 25,375 | 22,112 | 32,914 |
Other Revenue | -0 | -0 | - | - | -0 | - |
| 30,937 | 31,923 | 31,663 | 25,375 | 22,112 | 32,914 | |
Revenue Growth (YoY) | -10.14% | 0.82% | 24.78% | 14.76% | -32.82% | -8.05% |
Cost of Revenue | 27,527 | 28,412 | 31,047 | 24,107 | 20,493 | 28,986 |
Gross Profit | 3,409 | 3,511 | 616.3 | 1,269 | 1,619 | 3,928 |
Selling, General & Admin | 9,906 | 11,099 | 9,246 | 8,269 | 8,544 | 7,848 |
Research & Development | 427.76 | 436.61 | 448.27 | 573.04 | 879.91 | 562.3 |
Amortization of Goodwill & Intangibles | 298.5 | 296.46 | 73.65 | 5.24 | 1.47 | 60.63 |
Other Operating Expenses | 248.94 | 243.35 | 444.94 | 323.52 | 251.64 | 433.14 |
Operating Expenses | 11,684 | 12,789 | 7,159 | 11,444 | 12,813 | 9,261 |
Operating Income | -8,275 | -9,278 | -6,543 | -10,175 | -11,193 | -5,333 |
Interest Expense | -1,124 | -1,369 | -2,090 | -2,341 | -4,591 | -6,859 |
Interest & Investment Income | 312.3 | 379.78 | 654.29 | 301.52 | 167.66 | 576.37 |
Earnings From Equity Investments | -29,031 | -33,300 | -27,881 | -9,377 | 4,219 | -5,876 |
Currency Exchange Gain (Loss) | -927.8 | -1,216 | 7,204 | 520.54 | 1,760 | 2,388 |
Other Non Operating Income (Expenses) | -321.83 | 173.93 | 2,986 | -1,015 | -867.14 | 8,613 |
EBT Excluding Unusual Items | -39,366 | -44,609 | -25,669 | -22,086 | -10,505 | -6,491 |
Gain (Loss) on Sale of Investments | 0.73 | 0.58 | 0.58 | 16.29 | 2,520 | - |
Gain (Loss) on Sale of Assets | -14.76 | -84.35 | 11,804 | -2,559 | 328.51 | 650.04 |
Asset Writedown | -4,627 | -4,643 | -2,191 | -1,029 | -487.48 | -3,834 |
Pretax Income | -44,007 | -49,336 | -16,056 | -25,658 | -8,145 | -9,675 |
Income Tax Expense | -421.7 | -416.39 | -426.12 | 84.12 | - | 64.59 |
Earnings From Continuing Operations | -43,585 | -48,920 | -15,629 | -25,742 | -8,145 | -9,740 |
Earnings From Discontinued Operations | - | - | - | - | - | -775.31 |
Net Income to Company | -43,585 | -48,920 | -15,629 | -25,742 | -8,145 | -10,515 |
Minority Interest in Earnings | - | - | - | - | - | 484.68 |
Net Income | -43,585 | -48,920 | -15,629 | -25,742 | -8,145 | -10,030 |
Net Income to Common | -43,585 | -48,920 | -15,629 | -25,742 | -8,145 | -10,030 |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 27 | 25 |
Shares Outstanding (Diluted) | 28 | 28 | 29 | 28 | 27 | 27 |
Shares Change (YoY) | 0.03% | -2.36% | 4.78% | 3.72% | -0.50% | 25.82% |
EPS (Basic) | -1530.44 | -1718.37 | -549.00 | -925.06 | -303.58 | -398.47 |
EPS (Diluted) | -1530.47 | -1718.40 | -572.73 | -925.10 | -303.60 | -433.06 |
Free Cash Flow | -11,365 | -8,601 | -22,861 | -6,011 | -12,593 | -2,762 |
Free Cash Flow Per Share | -399.06 | -302.12 | -784.09 | -216.00 | -469.40 | -102.45 |
Gross Margin | 11.02% | 11.00% | 1.95% | 5.00% | 7.32% | 11.93% |
Operating Margin | -26.75% | -29.06% | -20.66% | -40.10% | -50.62% | -16.20% |
Profit Margin | -140.88% | -153.25% | -49.36% | -101.45% | -36.83% | -30.47% |
Free Cash Flow Margin | -36.73% | -26.94% | -72.20% | -23.69% | -56.95% | -8.39% |
EBITDA | -6,573 | -7,584 | -5,059 | -8,305 | -9,791 | -2,708 |
EBITDA Margin | -21.25% | -23.76% | -15.98% | -32.73% | -44.28% | -8.23% |
D&A For EBITDA | 1,701 | 1,694 | 1,484 | 1,870 | 1,402 | 2,625 |
EBIT | -8,275 | -9,278 | -6,543 | -10,175 | -11,193 | -5,333 |
EBIT Margin | -26.75% | -29.06% | -20.66% | -40.10% | -50.62% | -16.20% |
Advertising Expenses | - | - | 2.3 | 1.92 | 297.47 | 163.47 |